{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of preclinical development is translating safety data from animal models into a safe starting dose for human trials. This process is not a simple weight-based conversion; it relies on allometric scaling, which accounts for differences in physiology across species. This exercise  will guide you through the standard method of calculating the Human Equivalent Dose (HED) using body surface area normalization and applying a crucial safety factor to determine the Maximum Recommended Starting Dose (MRSD).",
            "id": "4981207",
            "problem": "A small-molecule candidate intended for oral administration completed a 28-day Good Laboratory Practice (GLP) rat toxicity study with a No Observed Adverse Effect Level (NOAEL) of $30$ $\\mathrm{mg \\cdot kg^{-1} \\cdot day^{-1}}$. Cross-species dose extrapolation for first-in-human planning should be grounded in body surface area normalization, where interspecies dose comparability is obtained by converting mass-normalized doses to surface-area-normalized doses using species-specific mass-to-surface area ratios. Let $K_{m}$ denote the species-specific mass-to-surface area ratio (kilograms per square meter). For the rat, $K_{m,\\mathrm{rat}}=6$, and for the human adult, $K_{m,\\mathrm{human}}=37$.\n\nUsing these data and starting from the principle that body surface area normalization yields comparable exposure across species, first determine the human equivalent dose (HED) on a mass-normalized basis in $\\mathrm{mg \\cdot kg^{-1}}$. Then, propose and justify a conservative composite safety factor suitable for a first-in-human single ascending dose study, and apply it to convert the HED into the Maximum Recommended Starting Dose (MRSD) in $\\mathrm{mg \\cdot kg^{-1}}$.\n\nRound the MRSD to four significant figures. Express the final result in $\\mathrm{mg \\cdot kg^{-1}}$. Report only the MRSD as your final numerical answer.",
            "solution": "The problem is valid as it is scientifically grounded in standard pharmacological principles for first-in-human dose selection, is well-posed with sufficient and consistent data, and is expressed with objective, precise language.\n\nThe first step is to calculate the Human Equivalent Dose (HED) from the No Observed Adverse Effect Level (NOAEL) observed in the rat toxicity study. The guiding principle is the normalization of dose to body surface area (BSA), which posits that doses expressed in units of mass per unit of BSA (e.g., $\\mathrm{mg \\cdot m^{-2}}$) are equivalent across different mammalian species.\n\nThe conversion between a mass-normalized dose ($D_{\\mathrm{mg/kg}}$, in units of $\\mathrm{mg \\cdot kg^{-1}}$) and a BSA-normalized dose ($D_{\\mathrm{mg/m^2}}$, in units of $\\mathrm{mg \\cdot m^{-2}}$) is accomplished using a species-specific factor, $K_m$, which represents the ratio of body mass to surface area ($\\mathrm{kg \\cdot m^{-2}}$). The relationship is given by:\n$$D_{\\mathrm{mg/m^2}} = D_{\\mathrm{mg/kg}} \\times K_m$$\n\nWe are given the following values:\n- Rat NOAEL, $D_{\\mathrm{rat}}$: $30 \\, \\mathrm{mg \\cdot kg^{-1} \\cdot day^{-1}}$\n- Rat $K_m$ factor, $K_{m, \\mathrm{rat}}$: $6 \\, \\mathrm{kg \\cdot m^{-2}}$\n- Human $K_m$ factor, $K_{m, \\mathrm{human}}$: $37 \\, \\mathrm{kg \\cdot m^{-2}}$\n\nFirst, we convert the rat NOAEL to a BSA-normalized dose:\n$$D_{\\mathrm{rat, \\, mg/m^2}} = D_{\\mathrm{rat, \\, mg/kg}} \\times K_{m, \\mathrm{rat}}$$\n$$D_{\\mathrm{rat, \\, mg/m^2}} = 30 \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}} \\times 6 \\, \\frac{\\mathrm{kg}}{\\mathrm{m^2}} = 180 \\, \\frac{\\mathrm{mg}}{\\mathrm{m^2}}$$\n\nAccording to the BSA normalization principle, the equivalent dose in humans on a $\\mathrm{mg \\cdot m^{-2}}$ basis is equal to this value. Let's call this $D_{\\mathrm{HED, \\, mg/m^2}}$:\n$$D_{\\mathrm{HED, \\, mg/m^2}} = D_{\\mathrm{rat, \\, mg/m^2}} = 180 \\, \\frac{\\mathrm{mg}}{\\mathrm{m^2}}$$\n\nTo find the HED in the required units of $\\mathrm{mg \\cdot kg^{-1}}$, we convert this BSA-normalized human dose back to a mass-normalized dose using the human $K_m$ factor:\n$$HED \\, (\\mathrm{mg/kg}) = \\frac{D_{\\mathrm{HED, \\, mg/m^2}}}{K_{m, \\mathrm{human}}}$$\n$$HED = \\frac{180 \\, \\frac{\\mathrm{mg}}{\\mathrm{m^2}}}{37 \\, \\frac{\\mathrm{kg}}{\\mathrm{m^2}}} = \\frac{180}{37} \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}}$$\n\nCombining these steps into a single formula for HED gives:\n$$HED = D_{\\mathrm{rat}} \\times \\frac{K_{m, \\mathrm{rat}}}{K_{m, \\mathrm{human}}}$$\n$$HED = 30 \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}} \\times \\frac{6}{37} = \\frac{180}{37} \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}}$$\n\nThe next step is to propose and justify a conservative composite safety factor ($SF$) to convert the HED into the Maximum Recommended Starting Dose (MRSD). For first-in-human studies of small-molecule drugs based on toxicity data from a rodent species, standard regulatory guidance (e.g., U.S. FDA, 2005) recommends a default safety factor of $SF = 10$. This factor is considered conservative and is justified by several sources of uncertainty in the extrapolation, including:\n1.  **Interspecies differences in sensitivity**: Despite BSA scaling, humans may be intrinsically more sensitive to the drug's effects than rats.\n2.  **Intraspecies variability**: The human population exhibits significant genetic and physiological variability, whereas the laboratory rats used in GLP studies are typically from a homogeneous, inbred strain. The safety factor provides a margin to protect a diverse population.\n3.  **Nature of the toxicity**: The NOAEL does not provide information on the steepness of the dose-toxicity curve or the severity of adverse effects at slightly higher doses (i.e., at the Lowest Observed Adverse Effect Level, or LOAEL). A factor of $10$ provides a buffer against potentially severe or irreversible toxicities.\n\nTherefore, a safety factor of $SF=10$ is appropriate and well-justified.\n\nThe final step is to calculate the MRSD by applying this safety factor to the HED:\n$$MRSD = \\frac{HED}{SF}$$\n$$MRSD = \\frac{\\frac{180}{37} \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}}}{10} = \\frac{18}{37} \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}}$$\n\nNow, we compute the numerical value and round to four significant figures as required:\n$$MRSD = \\frac{18}{37} \\approx 0.486486486... \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}}$$\nRounding to four significant figures gives:\n$$MRSD = 0.4865 \\, \\frac{\\mathrm{mg}}{\\mathrm{kg}}$$",
            "answer": "$$\\boxed{0.4865}$$"
        },
        {
            "introduction": "In repeated-dose toxicity studies, the drug concentration in the body doesn't stay the same after each dose; it often builds up or 'accumulates'. Understanding this phenomenon is vital for correctly interpreting toxicological findings, as the peak exposure at steady state can be much higher than after the first dose. This practice  delves into the pharmacokinetic principles of accumulation, asking you to derive and calculate the accumulation ratio to see how half-life and dosing frequency dictate steady-state exposure.",
            "id": "4981187",
            "problem": "A small-molecule candidate is being evaluated in a repeated-dose rodent toxicity study under linear, first-order pharmacokinetics and instantaneous input per dose. After a single oral dose, the concentration–time profile follows first-order elimination described by $ \\frac{dC}{dt} = -k\\,C $, where $k$ is the elimination rate constant. The half-life $t_{1/2}$ is defined as the time at which the concentration decreases to one-half of its initial value. The study uses a fixed dosing interval $\\tau$ between identical doses. For the purposes of exposure assessment, the accumulation ratio $R$ is defined as the ratio of the steady-state peak concentration immediately after a dose to the peak concentration immediately after the first dose.\n\nStarting from the differential equation for first-order elimination and the definition of half-life, and using only the assumptions stated, derive an expression for $R$ in terms of $k$ and $\\tau$. Next, express $R$ entirely in terms of $t_{1/2}$ and $\\tau$. Finally, for a test article with half-life $t_{1/2} = 18$ hours and dosing interval $\\tau = 12$ hours, compute the numerical value of $R$. Round your final numeric accumulation ratio to four significant figures. State your final numeric answer as a pure number without units, and in addition, explain briefly how this accumulation ratio would impact steady-state exposure interpretation in preclinical toxicity testing.",
            "solution": "The problem asks for the derivation of the accumulation ratio, $R$, under a specific pharmacokinetic model, its calculation for a given compound, and an interpretation of the result in the context of preclinical toxicity testing.\n\nThe validation process confirms that the problem is scientifically grounded, well-posed, objective, and contains sufficient information for a unique solution. The model described is a standard one-compartment pharmacokinetic model with first-order elimination and repeated bolus dosing.\n\nFirst, we must solve the differential equation describing first-order elimination to find the concentration-time profile after a single dose. The governing equation is:\n$$\n\\frac{dC}{dt} = -k\\,C\n$$\nwhere $C$ is the drug concentration at time $t$, and $k$ is the first-order elimination rate constant. This is a separable first-order ordinary differential equation. We rearrange and integrate:\n$$\n\\int \\frac{1}{C} dC = \\int -k\\,dt\n$$\n$$\n\\ln(C) = -kt + I\n$$\nwhere $I$ is the constant of integration. Exponentiating both sides gives:\n$$\nC(t) = \\exp(-kt + I) = \\exp(I) \\exp(-kt)\n$$\nLet the initial concentration at $t=0$ be $C(0) = C_0$. Substituting this gives $C_0 = \\exp(I)$, so the concentration at any time $t$ after a single dose is:\n$$\nC(t) = C_0 \\exp(-kt)\n$$\n\nNext, we derive the accumulation ratio $R$. The problem states that doses are identical and administered at a fixed interval $\\tau$. Let $C_{\\text{max},1}$ be the peak concentration immediately after the first dose. The concentration just before the second dose, at time $t=\\tau$, is the trough concentration after the first dose:\n$$\nC_{\\text{trough},1} = C_{\\text{max},1} \\exp(-k\\tau)\n$$\nImmediately after the second dose is administered, the peak concentration $C_{\\text{max},2}$ is the sum of the trough concentration and the concentration increase from the new dose, which is equal to $C_{\\text{max},1}$ (assuming linear pharmacokinetics and identical doses).\n$$\nC_{\\text{max},2} = C_{\\text{trough},1} + C_{\\text{max},1} = C_{\\text{max},1} \\exp(-k\\tau) + C_{\\text{max},1} = C_{\\text{max},1} (1 + \\exp(-k\\tau))\n$$\nSimilarly, the peak concentration after the third dose will be:\n$$\nC_{\\text{max},3} = C_{\\text{max},2} \\exp(-k\\tau) + C_{\\text{max},1} = C_{\\text{max},1} (1 + \\exp(-k\\tau)) \\exp(-k\\tau) + C_{\\text{max},1} = C_{\\text{max},1} (1 + \\exp(-k\\tau) + \\exp(-2k\\tau))\n$$\nBy induction, the peak concentration after the $n$-th dose is given by the sum of a finite geometric series:\n$$\nC_{\\text{max},n} = C_{\\text{max},1} \\sum_{i=0}^{n-1} (\\exp(-k\\tau))^i = C_{\\text{max},1} \\left( \\frac{1 - (\\exp(-k\\tau))^n}{1 - \\exp(-k\\tau)} \\right)\n$$\nSteady state is achieved as the number of doses $n$ approaches infinity. Since $k > 0$ and $\\tau > 0$, the term $\\exp(-k\\tau)$ is less than $1$, and thus $\\lim_{n \\to \\infty} (\\exp(-k\\tau))^n = 0$. The steady-state peak concentration, $C_{\\text{ss,max}}$, is therefore:\n$$\nC_{\\text{ss,max}} = \\lim_{n \\to \\infty} C_{\\text{max},n} = C_{\\text{max},1} \\left( \\frac{1}{1 - \\exp(-k\\tau)} \\right)\n$$\nThe accumulation ratio $R$ is defined as the ratio of the steady-state peak concentration to the peak concentration after the first dose:\n$$\nR = \\frac{C_{\\text{ss,max}}}{C_{\\text{max},1}} = \\frac{1}{1 - \\exp(-k\\tau)}\n$$\nThis is the expression for $R$ in terms of $k$ and $\\tau$.\n\nNext, we express $R$ in terms of the half-life $t_{1/2}$ and the dosing interval $\\tau$. The half-life is the time required for the concentration to decrease to half its initial value. Using the single-dose decay equation $C(t) = C_0 \\exp(-kt)$:\n$$\n\\frac{1}{2} C_0 = C_0 \\exp(-k t_{1/2})\n$$\n$$\n\\frac{1}{2} = \\exp(-k t_{1/2})\n$$\nTaking the natural logarithm of both sides:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k t_{1/2} \\implies -\\ln(2) = -k t_{1/2}\n$$\nSolving for $k$ gives the relationship between the elimination rate constant and the half-life:\n$$\nk = \\frac{\\ln(2)}{t_{1/2}}\n$$\nSubstituting this expression for $k$ into our equation for $R$:\n$$\nR = \\frac{1}{1 - \\exp\\left(-\\frac{\\ln(2)}{t_{1/2}}\\tau\\right)} = \\frac{1}{1 - \\exp\\left(\\ln(2) \\cdot \\left(-\\frac{\\tau}{t_{1/2}}\\right)\\right)}\n$$\nUsing the identity $\\exp(\\ln(a) \\cdot b) = a^b$, we simplify the expression:\n$$\nR = \\frac{1}{1 - 2^{-\\tau/t_{1/2}}}\n$$\nThis is the expression for $R$ in terms of $t_{1/2}$ and $\\tau$.\n\nNow, we compute the numerical value of $R$ for the given parameters: $t_{1/2} = 18$ hours and $\\tau = 12$ hours. The ratio of the dosing interval to the half-life is:\n$$\n\\frac{\\tau}{t_{1/2}} = \\frac{12}{18} = \\frac{2}{3}\n$$\nSubstituting this ratio into the expression for $R$:\n$$\nR = \\frac{1}{1 - 2^{-2/3}} = \\frac{1}{1 - (1/2)^{2/3}}\n$$\nCalculating the numerical value:\n$$\nR = \\frac{1}{1 - 0.5^{2/3}} \\approx \\frac{1}{1 - 0.62996052} \\approx \\frac{1}{0.37003948} \\approx 2.7024107\n$$\nRounding to four significant figures, the accumulation ratio is $2.702$.\n\nFinally, we explain the impact of this accumulation ratio on steady-state exposure interpretation. An accumulation ratio of $R \\approx 2.702$ indicates that the peak drug concentration at steady state ($C_{\\text{ss,max}}$) will be approximately $2.7$ times higher than the peak concentration observed after the very first dose ($C_{\\text{max},1}$). This constitutes a significant degree of drug accumulation. In the context of a preclinical toxicity study, this has critical implications. If toxicity is driven by peak concentrations, any adverse effects may not be apparent after a single dose but could emerge and intensify over several days of repeated dosing as the drug accumulates toward its steady-state levels. Therefore, the toxicological risk of the compound cannot be adequately assessed from single-dose data. The study must be designed with a duration sufficient to allow the drug to reach steady state, which is conventionally taken to be $3$ to $5$ half-lives. For this compound, with a half-life of $18$ hours, this would be $54$ to $90$ hours (approximately $2$ to $4$ days). The interpretation of all toxicity findings, particularly the establishment of a No-Observed-Adverse-Effect Level (NOAEL), must be based on the higher, more clinically relevant exposures achieved at steady state, not the transient, lower exposures seen at the beginning of the study.",
            "answer": "$$\n\\boxed{2.702}\n$$"
        },
        {
            "introduction": "Ideal drugs exhibit linear pharmacokinetics, where exposure increases proportionally with the dose. However, biological systems have limits, and processes like drug absorption can become saturated, leading to non-linear and less-than-proportional exposure increases. This scenario presents a major challenge in toxicology, as achieving high exposure multiples over the therapeutic dose becomes difficult. This advanced problem  places you in the role of a toxicologist, tasking you with analyzing non-linear pharmacokinetic data and devising a new dosing strategy to achieve the required safety margins.",
            "id": "4981213",
            "problem": "A small-molecule candidate was evaluated in a $13$-week oral rat toxicity study with once-daily administration at three dose levels: low $50$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$, mid $150$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$, and high $450$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$. Measured steady-state area under the concentration–time curve (AUC) over $24$ hours, denoted $\\mathrm{AUC}_{0-24,\\mathrm{ss}}$, was $20$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$ at the low dose, $60$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$ at the mid dose, and $90$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$ at the high dose. These results show dose-proportional exposure from low to mid dose and a plateau at the high dose consistent with capacity-limited absorption per administration.\n\nAssume the following:\n- At low and mid doses, the fraction absorbed (bioavailability) is constant, $F=0.5$.\n- Systemic elimination is linear with a constant clearance $CL$ that does not change with dose.\n- The formulation exhibits a per-administration absorption capacity: at most $A_{\\mathrm{cap}}$ $\\mathrm{mg\\cdot kg^{-1}}$ can be absorbed from any single administration, regardless of how much is given. When the administered amount is sufficiently large, each administration absorbs $A_{\\mathrm{cap}}$.\n- At steady state, mass balance over $24$ hours implies that $\\mathrm{AUC}_{0-24,\\mathrm{ss}} = \\dfrac{M_{\\mathrm{abs,24h}}}{CL}$, where $M_{\\mathrm{abs,24h}}$ is the total absorbed amount over $24$ hours.\n\nThe human therapeutic steady-state $\\mathrm{AUC}_{0-24}$ is $6$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$. To ensure a supra-therapeutic safety margin in rats, you aim for a rat steady-state $\\mathrm{AUC}_{0-24}$ equal to $20$ times the human value.\n\nYou plan to adjust the rat regimen to $n$ equally spaced oral administrations per day, each with a sufficiently large per-dose amount such that the per-administration absorption saturates at $A_{\\mathrm{cap}}$ (thus maximizing absorbed amount per administration). Under these assumptions, determine the smallest integer $n$ required so that the maximum achievable rat $\\mathrm{AUC}_{0-24,\\mathrm{ss}}$ meets or exceeds the target supra-therapeutic exposure. Report only the value of $n$ as your final answer.",
            "solution": "The problem asks for the smallest integer number of daily administrations, $n$, required to achieve a target systemic exposure in rats. The solution requires a multi-step quantitative analysis based on pharmacokinetic principles.\n\nFirst, we validate the problem statement.\nGivens are extracted verbatim:\n- Study: $13$-week oral rat toxicity study, once-daily administration.\n- Doses: Low $D_{\\mathrm{low}} = 50$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$, Mid $D_{\\mathrm{mid}} = 150$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$, High $D_{\\mathrm{high}} = 450$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$.\n- Steady-state AUCs: $\\mathrm{AUC}_{\\mathrm{low}} = 20$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$, $\\mathrm{AUC}_{\\mathrm{mid}} = 60$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$, $\\mathrm{AUC}_{\\mathrm{high}} = 90$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$.\n- Observation: Dose-proportional exposure low to mid dose; plateau at high dose.\n- Assumption 1: For low and mid doses, bioavailability $F = 0.5$.\n- Assumption 2: Systemic clearance $CL$ is constant.\n- Assumption 3: Per-administration absorption capacity is $A_{\\mathrm{cap}}$ $\\mathrm{mg\\cdot kg^{-1}}$.\n- Assumption 4: $\\mathrm{AUC}_{0-24,\\mathrm{ss}} = \\frac{M_{\\mathrm{abs,24h}}}{CL}$, where $M_{\\mathrm{abs,24h}}$ is the total absorbed amount over $24$ hours.\n- Human therapeutic AUC: $\\mathrm{AUC}_{\\mathrm{human}} = 6$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$.\n- Target safety margin: $20$ times the human value.\n- New regimen: $n$ administrations per day, each saturating absorption.\n- Objective: Find the smallest integer $n$ to meet or exceed the target exposure.\n\nThe problem is scientifically grounded in standard pharmacokinetics, is well-posed with sufficient and consistent data, and is expressed objectively. The dose-proportionality check confirms consistency: tripling the dose from $50$ to $150$ $\\mathrm{mg\\cdot kg^{-1}}$ triples the AUC from $20$ to $60$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$. The plateau at the high dose is consistent with saturation. The problem is deemed valid.\n\nThe solution proceeds as follows:\n\n1.  Calculate the target steady-state rat $\\mathrm{AUC}_{0-24,\\mathrm{ss}}$, denoted $\\mathrm{AUC}_{\\mathrm{target}}$.\n    The target exposure is $20$ times the human therapeutic value.\n    $$\n    \\mathrm{AUC}_{\\mathrm{target}} = 20 \\times \\mathrm{AUC}_{\\mathrm{human}} = 20 \\times 6 \\ \\mathrm{mg\\cdot h\\cdot L^{-1}} = 120 \\ \\mathrm{mg\\cdot h\\cdot L^{-1}}\n    $$\n\n2.  Calculate the systemic clearance, $CL$.\n    The problem states that clearance is constant. We can calculate it from the dose range where absorption is not saturated (low and mid doses). The relationship is given by $\\mathrm{AUC}_{0-24,\\mathrm{ss}} = \\frac{M_{\\mathrm{abs,24h}}}{CL}$. For once-daily dosing in the linear range, the total absorbed amount over $24$ hours is $M_{\\mathrm{abs,24h}} = F \\cdot D$, where $D$ is the daily dose in $\\mathrm{mg\\cdot kg^{-1}}$.\n    Thus, $CL = \\frac{F \\cdot D}{\\mathrm{AUC}_{0-24,\\mathrm{ss}}}$.\n    Using the low-dose data: $D_{\\mathrm{low}} = 50$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$, $\\mathrm{AUC}_{\\mathrm{low}} = 20$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$, and $F=0.5$.\n    The amount absorbed is $M_{\\mathrm{abs,low}} = 0.5 \\times 50 \\ \\mathrm{mg\\cdot kg^{-1}} = 25 \\ \\mathrm{mg\\cdot kg^{-1}}$.\n    $$\n    CL = \\frac{25 \\ \\mathrm{mg\\cdot kg^{-1}}}{20 \\ \\mathrm{mg\\cdot h\\cdot L^{-1}}} = 1.25 \\ \\mathrm{L\\cdot h^{-1}\\cdot kg^{-1}}\n    $$\n    Verification with mid-dose data: $D_{\\mathrm{mid}} = 150$ $\\mathrm{mg\\cdot kg^{-1}\\cdot day^{-1}}$ and $\\mathrm{AUC}_{\\mathrm{mid}} = 60$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$.\n    The amount absorbed is $M_{\\mathrm{abs,mid}} = 0.5 \\times 150 \\ \\mathrm{mg\\cdot kg^{-1}} = 75 \\ \\mathrm{mg\\cdot kg^{-1}}$.\n    $$\n    CL = \\frac{75 \\ \\mathrm{mg\\cdot kg^{-1}}}{60 \\ \\mathrm{mg\\cdot h\\cdot L^{-1}}} = \\frac{5}{4} \\ \\mathrm{L\\cdot h^{-1}\\cdot kg^{-1}} = 1.25 \\ \\mathrm{L\\cdot h^{-1}\\cdot kg^{-1}}\n    $$\n    The clearance value is consistent.\n\n3.  Calculate the per-administration absorption capacity, $A_{\\mathrm{cap}}$.\n    At the high dose of $D_{\\mathrm{high}} = 450$ $\\mathrm{mg\\cdot kg^{-1}}$, given once daily, absorption is saturated. The amount absorbed from this single administration is $A_{\\mathrm{cap}}$. Therefore, the total amount absorbed over $24$ hours is $M_{\\mathrm{abs,high}} = A_{\\mathrm{cap}}$.\n    Using the high-dose data ($\\mathrm{AUC}_{\\mathrm{high}} = 90$ $\\mathrm{mg\\cdot h\\cdot L^{-1}}$) and the calculated clearance:\n    $$\n    A_{\\mathrm{cap}} = M_{\\mathrm{abs,high}} = \\mathrm{AUC}_{\\mathrm{high}} \\times CL = (90 \\ \\mathrm{mg\\cdot h\\cdot L^{-1}}) \\times (1.25 \\ \\mathrm{L\\cdot h^{-1}\\cdot kg^{-1}})\n    $$\n    $$\n    A_{\\mathrm{cap}} = 90 \\times \\frac{5}{4} \\ \\mathrm{mg\\cdot kg^{-1}} = \\frac{450}{4} \\ \\mathrm{mg\\cdot kg^{-1}} = 112.5 \\ \\mathrm{mg\\cdot kg^{-1}}\n    $$\n\n4.  Determine the minimum integer $n$ for the new regimen.\n    The new regimen involves $n$ administrations per day, with each administration large enough to saturate the absorption process. Thus, for each of the $n$ administrations, the amount absorbed is $A_{\\mathrm{cap}}$.\n    The total amount absorbed over $24$ hours is $M_{\\mathrm{abs,total}} = n \\cdot A_{\\mathrm{cap}}$.\n    The resulting steady-state AUC is $\\mathrm{AUC}_{\\mathrm{new}} = \\frac{n \\cdot A_{\\mathrm{cap}}}{CL}$.\n    We need to find the smallest integer $n$ that satisfies $\\mathrm{AUC}_{\\mathrm{new}} \\ge \\mathrm{AUC}_{\\mathrm{target}}$.\n    $$\n    \\frac{n \\cdot A_{\\mathrm{cap}}}{CL} \\ge \\mathrm{AUC}_{\\mathrm{target}}\n    $$\n    Solving for $n$:\n    $$\n    n \\ge \\frac{\\mathrm{AUC}_{\\mathrm{target}} \\cdot CL}{A_{\\mathrm{cap}}}\n    $$\n    Substituting the determined values:\n    $$\n    n \\ge \\frac{(120 \\ \\mathrm{mg\\cdot h\\cdot L^{-1}}) \\cdot (1.25 \\ \\mathrm{L\\cdot h^{-1}\\cdot kg^{-1}})}{112.5 \\ \\mathrm{mg\\cdot kg^{-1}}}\n    $$\n    $$\n    n \\ge \\frac{150}{112.5}\n    $$\n    To simplify the fraction, we can write $112.5 = \\frac{225}{2}$.\n    $$\n    n \\ge \\frac{150}{\\frac{225}{2}} = \\frac{150 \\times 2}{225} = \\frac{300}{225} = \\frac{4 \\times 75}{3 \\times 75} = \\frac{4}{3}\n    $$\n    The condition is $n \\ge \\frac{4}{3}$, which is approximately $n \\ge 1.333...$.\n    Since $n$ must be an integer representing the number of administrations per day, the smallest integer value for $n$ satisfying this inequality is $2$.",
            "answer": "$$\\boxed{2}$$"
        }
    ]
}